Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 2Completed 2Unknown 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Nasopharyngeal Carcinoma 19Triple Negative Breast Neoplasms 11Breast Neoplasms 10Carcinoma, Non-Small-Cell Lung 8Advanced Solid Tumor 6Squamous Cell Carcinoma of Head and Neck 5Neoplasms 5Head and Neck Neoplasms 5Colorectal Neoplasms 5Uterine Cervical Neoplasms 4Stomach Neoplasms 4Esophageal Squamous Cell Carcinoma 4Carcinoma, Transitional Cell 4Carcinoma, Renal Cell 4Solid Tumor 3Small Cell Lung Carcinoma 3Recurrence 3Rectal Neoplasms 3Turcot syndrome 2Sarcoma 2Ovarian Neoplasms 2Oropharyngeal Neoplasms 2Neoplasm Metastasis 2Nasopharyngeal Neoplasms 2Microsatellite Stable Metastatic Colorectal Cancer 2Locally Advanced Rectal Cancer 2Liposarcoma 2Laryngeal Neoplasms 2Gestational Trophoblastic Disease 2Esophageal Neoplasms 2

Interventions

Injections 16pembrolizumab 6Bevacizumab 6Paclitaxel 4Leucovorin 4Fluorouracil 4Carboplatin 4fludarabine 3Pemetrexed 3Oxaliplatin 3Capecitabine 3toripalimab 2sotorasib 2Immune Checkpoint Inhibitors 2Fulvestrant 2Drug Therapy 2Docetaxel 2Cyclophosphamide 2Cisplatin 2130-nm albumin-bound paclitaxel 2zimberelimab 1trifluridine tipiracil drug combination 1trametinib 1tislelizumab 1sacituzumab govitecan 1palbociclib 1osimertinib 1olaparib 1lazertinib 1fluzoparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Advanced Solid Tumors × toripalimab × Clear all
NCT06832982 2026-04-09

Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacokinetics, and Preliminary Efficacy of FS-8002

Shanghai Pushi Medical Science Co. Ltd

Phase 1 Recruiting
66 enrolled
Other solid neoplasm

Advanced Solid Tumors

NCT06208410 2025-07-25

A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors

Risen (Suzhou) Pharma Tech Co., Ltd.

Phase 1/2 Recruiting
306 enrolled
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡